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1. Introduction
Infections caused by bacteria of genus Acinetobacter pose a significant health care challenge
worldwide (Munoz-Price & Weinstein, 2008; Visca et al., 2011). Acinetobacter infections in the
past were sporadically identified in hospitalized patients and hospital infection outbreaks in
intensive care units. But, nowadays Acinetobacter has emerged as an important healthcare-
associated and multidrug-resistant microorganism (Peleg at al., 2008).
Acinetobacter was first described in 1911 by Beijerinck as Micrococcus calco-aceticus. The
name “Acinetobacter” originates from the Greek word “akinetos” meaning “unable to move”,
as these bacteria are not motile. A. baumannii, A. calcoaceticus, A. haemolyticus and A. lwoffii
are the most important species in clinical practice.
Acinetobacter species are ubiquitous in nature and have been found in soil, water, animals
and humans. Some strains of Acinetobacter can survive for weeks in environment, promoting
transmission within the hospital settings (Doughari et al., 2011). Acinetobacter baumannii was
recovered from the skin, throat, rectum and respiratory tract of humans. The species A.
baumannii accounts for nearly 80% of reported Acinetobacter infections (CDC,2007). This
feature along with antimicrobial resistance, colonization potential and contact transmission
are main challenges for prevention and control activities (Maragakis et al., 2008). Some strains
of Acinetobacter produce verotoxins and others have been identified to have an impact on
removal of biological phosphorus from wastewater.
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2. Taxonomy and main features
Genus Acinetobacter belongs to the family Moraxellaceae and order Pseudomonadales.
Based on molecular studies, 32 species of Acinetobacter have now been recognized; 22 of them
have assigned valid names, whereas other species are described as a “genomic” group. The
most important clinical species in medicine is Acinetobacter baumannii. This micro-organism
has phenotypicall similarities with a group of species known as A.calcoaceticus-A.baumannii
complex (Vaneechoutte et al., 2011). In healthcare settings, this group is implicated in major
outbreaks and healthcare-associated infections.
The genus Acinetobacter consists of strictly aerobic Gram-negative coccobacilli rods, which
are nonmotile, catalase-positive, indole-negative, oxidase-negative, non-fermentative. The
bacilli are 0.9 to 1.6 μm in diameter and 1.5 to 2.5 μm in length, often in pairs or assembled
into longer chains. Acinetobacter spp. are non-fastidious and can be grown on standard
laboratory media.
Acinetobacter is relatively nonreactive in many biochemical tests used to differentiate among
gram-negative bacilli. Most clinical microbiology laboratories identify members of the genus
Acinetobacter at the level of the following three groups with corresponding metabolic
attributes (Allen et al., 2006):
• Acinetobacter calcoaceticus-baumannii complex: glucose-oxidizing non-hemolytic (A.bau‐
mannii can be identified by OXA-51 serotyping)
• Acinetobacter lwoffii: non glucose-oxidizing, non-hemolytic
• Acinetobacter haemolyticus: hemolytic.
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Figure 1. Colonies of Acinetobacter spp. on sheep’s blood agar after 24 hours at 37°C. CDC/ Pete Seidel. Public Health
Image Library
Acinetobacter species are widely distributed in nature and can be found in soil, sewage, water,
consumables (including fruits and vegetables), and on healthy skin and other body sites. A.
baumannii can be found also in some unusual reservoirs, such as food or arthropods. The
majority of A. baumannii strains survive longer than Escherichia coli on dry surfaces, and some
strains survive for more than 4 months.
About 25% of adults carry this organism on their skin, whereas about 7% carry it in their
pharynx.  Hospitalized  patients  may  become  easily  colonized.  Half  of  the  patients  with
tracheostomy may be colonized with Acientobacter. Isolation of this microorganism from
feces, urine, vaginal secretions is often considered as colonization or contamination. But,
their  presence  from  immunocompromised  persons  may  have  significant  clinical  impact
(Mahon et al., 2010).
Clinical infections with Acinetobacter in healthcare settings are related to the use of invasive
procedures (mechanical ventilation, vascular catheters) and patient’s underlying conditions
(Fournier & Richet, 2006). The most important risk factors for acquiring Acinetobacter
infections are: prior antibiotic use (third-generation cephalosporins, fluoroquinolones or
carbapenems), prolonged hospitalization, high APACHE II (Acute Physiology and Chronic
Health Evaluation) score, recent surgical intervention, central vascular catheterization,
tracheostomy, mechanical ventilation and enteral feeding.
Acinetobacter can contaminate many surfaces and medical equipment, such are: suctioning
equipment, washbasins, bedrails, bedside tables, ventilators, sinks, pillows, mattresses,
hygroscopic bandages, resuscitation equipment, and trolleys (Bernards et al., 2004). The hands
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of healthcare workers are in frequent contact with these objects in patient surroundings. Hands
become an important vectors of transmission in case of non-compliance with hand hygiene
recommendations (Pittet et al., 2006). The ability of Acinetobacter to participate in biofilm
formation promotes durability in surfaces and may contribute to continuation of environmen‐
tal presence during outbreaks (Fournier et al., 2006).
Acinetobacter species posses the following virulence factors which enable transmission within
health care settings: cell surface hydrophobicity, enzymes, toxic slime polysaccharides,
verotoxins, siderophores and outer membrane proteins.
3. Clinical importance — Infections and outbreaks
Acinetobacter spp. can cause infections in both hospital settings and in community. They are
the second most commonly isolated non-fermenters in human specimens, after Pseudomonas
aeruginosa. About 1-3% of health care-associated infections are caused by Acientobacter spp.
Acinetobacter poses little risk to healthy people. However, people who have weakened
immune systems, chronic lung disease, or diabetes may be more susceptible to infections with
Acinetobacter. Most infections caused by this multiresistant bacteria involve organ systems,
which have a high fluid content (the respiratory tract, peritoneal fluid, and the urinary tract)
and are associated with usage of indwelling devices. The distribution of the different types of
hospital acquired infections is variable between hospitals and it depends on the hospital
population and the type of performed procedures and interventions. Rates of mortality from
Acinetobacter infections have a wide range from 5% in general wards to 54% in intensive care
units (Kempf & Rolain, 2012).
One important feature of A. baumannii is its ability to cause outbreaks, which is in relation to
antimicrobial resistance and resistance to desiccation (D’Agata et al., 2000; Villegas et Hart‐
stein, 2003). Acinetobacter spp. cause a wide range of health care-associated infections such
as: ventilator-associated pneumonia, bloodstream infections, urinary tract infections, surgical
site infections, meningitis, cholangitis, peritonitis, skin and wound infections, ventriculitis,
and infective endocarditis. Suppuration is common feature in infections caused by Aciento‐
bacter (abscesses of the brain, lung and the thyroid; secondary infections of wounds or surgical
trauma, and purulent lesions of the eye).
Acinetobacter can also cause infections in the community (Falagas et al., 2007). The predomi‐
nant community-acquired infections are: pneumonia, meningitis, cellulitis and bacteremia.
High fatality rates in community were correlated to underlying conditions and risk factors,
such as : alcoholism, diabetes and cancer.
Acinetobacter infections were also frequently reported during the natural disasters and wars
(Iraq, Kuwait and Afghanistan wars). Pathogenic Acinetobacter infections were encountered
in military personnel during the wars in Afghanistan and Iraq (O'Shea, 2012).Therefore it was
named by media as Iraqibacter.
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Recent disasters suggested that Acinetobacter infections should be taken in consideration in
differential diagnosis of soft-tissue infections (Asia tsunami on 2004).
Many Acinetobacter infections have a seasonal variation with 50% infection rates higher from
July to October than at other times of the year. This variation was explained by warmer, more
humid ambient air, which favors growth of Acinetobacter and potentially preventable
environmental contaminants, such as condensate from air-conditioners.
4. Antimicrobial resistance
The main challenge with A. baumannii is it’s ability to acquire antimicrobial-resistance genes
extremely rapidly, leading to multidrug resistance. Widespread use of antimicrobials within
hospitals resulted to the emergence and increase of antimicrobial resistance among Acineto‐
bacter strains, in particular, the wide use of extended-spectrum cephalosporins and quinolones
(Imperi et al, 2011).
Acinetobacter spp. are intrinsically less susceptible to antimicrobial agents than other repre‐
sentatives from the family Enterobacteriaceae. Various mechanisms played a role in the
acquisition of a multiresistance phenotype amongst Gram-negative bacteria, including
Acinetobacter strains such as: loss of porins, production of β-lactamases, increased expression
of efflux pumps, presence of antibiotic-modifying enzymes, target site mutations, ribosomal
mutations or modifications, metabolic bypass mechanisms and a mutation in the lipopolysac‐
charide (Poirel et al, 2011). The role of plasmids in the acquisition of antimicrobial resistance
in A. baumannii is mostly related to their integron structures.
Acinetobacter spp have ability to acquire antimicrobial-resistance genes rapidly, leading to
multidrug resistance. As a result, the clinical management of these infections has become a
public health challenge in many countries. Nowadays, the most serious problem in the
treatment of Acinetobacter infection is acquired multidrug-resistance, leaving only few
antimicrobial agents as treatment options. This resistance is attributed to the presence of
multiple resistant determinant among bacteria, which confers resistance to many groups of
antimicrobial agents (Livermore, 2012). One of the main concerns about antimicrobial resist‐
ance in A.baumannii has been the resistance to the last line of antimicrobials through acquis‐
ition of carbapenem resistance - mainly through the acquisition of B and D class
carbapenemases(Bou et al., 2012).
5. Detection and typing systems
Infection or colonization with Acinetobacter is usually diagnosed by the culture of clinical
samples and samples from environment. The most frequent clinical samples include blood,
cerebrospinal fluid, endotracheal aspirate, wounds, sputum, urine, catheter tips, stool or sterile
body fluid, skin, cordon of newborns, nasal swabs, hand swabs of hospital workers. The most
Acinetobacter
http://dx.doi.org/10.5772/55618
87
common environmental samples include swabs on surfaces of machines, wash-hand basins,
floors, tables, UV lamps, etc.
Microbiologic cultures can be processed by standard methods on routine media. For routine
clinical and laboratory investigations, traditional culture media are used: agar, brain heart
infusion agar, tryptic soy agar, Eosin-methylene blue, MacConkey agar, Violet red bile agar,
Luria Bertani agar and Holton medium. For environmental screening the most commonly used
media are broth media such as MacConkey’s broth, trypton soy, Brain Heart Infusion and Luria
broth. Antimicrobial susceptibility can be determined by various means, with the agar-dilution
method being the gold-standard (CLSI, 2011).
Biochemical typing methods include the use of colorimetric based GN card ID 32 GN, API
20NE, RapID NF Plus and Vitek 2 systems.
For detection of Acinetobacter strains a new molecular identification and typing methods have
been developed, leading to successful identification and outbreak management (Ecker et al., 2006).
The most important of them are : polymerase chain reaction (PCR), PFGE, RAPD-PCR DNA
fingerprinting, fluorescent in situ hybridization (FISH), 16S rRNA gene restriction analysis
(ARDRA) (amplified rDNA restriction analysis) and 16S rRNA gene PCR-DGGE (Denaturing
Gradient Gel Electrophoresis) fingerprinting (Versalovic et al., 2011). A recent diagnostic method
which was reported to have high specificity and can discriminate between Acinetobacter species
is the microsphere-based array technique that combines an allele specific primer extension assay
and microsphere hybridization. The use of DNA-DNA hybridization and sequence analysis is
considered the gold standard, but the method is time consuming and impractical in most clinical
laboratories.
Other methods that have been introduced in the epidemiological investigation of outbreaks
caused by Acinetobacter spp. include biotyping, phage typing, cell envelope protein typing,
plasmid typing, ribotyping, restriction fragment length polymorphisms and arbitrarily primed
PCR (AP-PCR).
6. Treatment, prevention and control
Treatment of Acinetobacter infections should be individualized according to results of
susceptibility testings. For effective treatment of Acinetobacter infections the combination
therapy is usually required. Infections caused by antibiotic-susceptible Acinetobacter isolates
have usually been treated with broad-spectrum cephalosporins, combinations of β-lactam:β-
lactamase inhibitor or carbapenems, used alone or in combination with an aminoglycoside
(Evans et al., 2012). The duration of treatment is similar to that for infections caused by other
gram-negative bacilli.
Antibiotic choices may be limited in cases of infections caused by multidrug-resistant isolates.
The emergence of multidrug-resistant Acinetobacter strains has brought the old antibiotic
polymyxins back into clinical use. These antibiotics disrupt bacterial cytoplasmic membranes,
causing leakage of cytoplasmic contents. Clinicians stoped using this antibiotic in 1970s due
to several side effects in kidneys and neurons.
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Another treatment option remain tigecycline, a new glycylcycline antibiotic. However,
development of resistance to these last option antibiotics has been reported recently (Gimar‐
ellou & Poulakou, 2012).
Prevention and control of infections caused by Acinetobacter requires a coordinated effort
involving all stakeholders including healthcare facilities and providers, public health, and
industry (Siegel et al., 2007). CDC and APIC has recommend the cornerstones for prevention
and control of multidrug resistant organisms, including Acinetobacter infections (CDC,2012;
APIC,2010). Key measures to control spread of multi-drug resistant organisms are:
• Administrative Measures/Adherence Monitoring
• Education
• Judicious Antimicrobial Use
• Surveillance
• Infection Control Precautions to Prevent Transmission
• Environmental Measures Decolonization
Infection control measures should start with strict isolation and cohorting of infected or colon‐
ized patients accompanied by administrative measures, education, prudent antimicrobial use,
surveillance, standard precautions to prevent transmission and environmental measures.
Control of hospital outbreaks caused by Acinetobacter species is an important challenge for all
health care settings. If a source and/or reservoir are identified, than the outbreak is successfully
controlled by the eradication of that source/reservoir. In other circumstances, various measures
may be used, including unit closure, cohorting of patients and staff, strict hand hygiene, contact
or strict isolation, environmental disinfection and discharge of colonized patients.
A review of 51 hospital outbreaks showed that 25 had a common source: 13 outbreaks with
predominantly respiratory tract infections and 12 with predominantly bloodstream or other
infections were controlled by removal or disinfection and sterilization of contaminated
ventilator (or related) equipment or contaminated moist fomites (Villegas & Hartstein, 2003).
When neither common sources nor environmental reservoirs are identified, control has
depended on active surveillance and contact isolation for colonized and infected patients,
improvements in the hand hygiene of health care workers and aseptic care of vascular catheters
and endotracheal tubes.
7. Conclusions
In conclusion, Acinetobacter strains are important pathogens due to the diversity of their
reservoirs, capacity to accumulate mechanisms of antimicrobial resistance and outbreak
potential. Acinetobacter infections prolong the length of hospital stay, increase mortality and
have economic impact. The greatest challenge remain prevention, control and treatment of
infections caused by multidrug-resistant strains of Acinetobacter.
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Although our understanding of Acinetobacter made an significant step forward, there are still
many unanswered questions for health care workers. Future directions should be directed
toward research development of new antibiotics, well-controlled clinical trials of antimicrobial
regimens and combinations, and prevention of health care-associated transmission of multi‐
drug-resistant Acinetobacter infections.
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